Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer

SIMPLE SUMMARY: Adavosertib is a first-in-class Wee1 inhibitor that has demonstrated activity against certain cancers. We evaluated the effects of adavosertib in treating differentiated thyroid cancer (DTC) using four DTC cell lines (BHP7-13, K1, FTC-133, FTC-238). Adavosertib accumulated cells in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yu-Ling, Wu, Ming-Hsien, Lee, Yi-Yin, Chou, Ting-Chao, Wong, Richard J., Lin, Shu-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306685/
https://www.ncbi.nlm.nih.gov/pubmed/34298699
http://dx.doi.org/10.3390/cancers13143487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306685/
https://www.ncbi.nlm.nih.gov/pubmed/34298699
http://dx.doi.org/10.3390/cancers13143487

Ejemplares similares